FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 125 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 The Cancer Moonshot: Moving from Planning to Research November 19, 2018 FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 EMA Recommends Extension of Indications for Durvalumab July 27, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the... GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... Connecting and Celebrating
